IL37 and allergic asthma: In ovalbumin- (OVA-) induced mouse acute asthma model, use of IL-37 nasal inhalation therapy effectively alleviated allergic airway inflammation, decreased the expression levels of a variety of proinflammatory cytokines, and reduced mucus production and airway hyperresponsiveness, indicating that IL-37 can relieve allergic asthma mediated by Th2 cells [70].